Nej Mo A 0907328
Nej Mo A 0907328
Nej Mo A 0907328
n e w e ng l a n d j o u r na l
of
m e dic i n e
original article
A bs t r ac t
Background
The use of valproic acid in the first trimester of pregnancy is associated with an increased risk of spina bifida, but data on the risks of other congenital malformations
are limited.
Methods
We first combined data from eight published cohort studies (1565 pregnancies in
which the women were exposed to valproic acid, among which 118 major malformations were observed) and identified 14 malformations that were significantly more
common among the offspring of women who had received valproic acid during the
first trimester. We then assessed the associations between use of valproic acid during
the first trimester and these 14 malformations by performing a casecontrol study
with the use of the European Surveillance of Congenital Anomalies (EUROCAT)
antiepileptic-study database, which is derived from population-based congenitalanomaly registries. Registrations (i.e., pregnancy outcomes with malformations
included in EUROCAT) with any of these 14 malformations were compared with
two control groups, one consisting of infants with malformations not previously
linked to valproic acid use (control group 1), and one consisting of infants with
chromosomal abnormalities (control group 2). The data set included 98,075 live
births, stillbirths, or terminations with malformations among 3.8 million births in
14 European countries from 1995 through 2005.
Results
Exposure to valproic acid monotherapy was recorded for a total of 180 registrations,
with 122 registrations in the case group, 45 in control group 1, and 13 in control
group 2. As compared with no use of an antiepileptic drug during the first trimester (control group 1), use of valproic acid monotherapy was associated with significantly increased risks for 6 of the 14 malformations under consideration; the adjusted odds ratios were as follows: spina bifida, 12.7 (95% confidence interval [CI],
7.7 to 20.7); atrial septal defect, 2.5 (95% CI, 1.4 to 4.4); cleft palate, 5.2 (95% CI, 2.8
to 9.9); hypospadias, 4.8 (95% CI, 2.9 to 8.1); polydactyly, 2.2 (95% CI, 1.0 to 4.5);
and craniosynostosis, 6.8 (95% CI, 1.8 to 18.8). Results for exposure to valproic acid
were similar to results for exposure to other antiepileptic drugs.
From the Department of Pharmacoepidemiology and Pharmacoeconomics, Division of Pharmacy, University of Groningen, Groningen, the Netherlands (J.J.,
L.T.W.J.-B.); the EUROCAT Central Registry, Institute of Nursing Research and
School of Nursing, University of Ulster,
Northern Ireland, United Kingdom (M.A.L.,
H.D.); Childrens University Hospital Zagreb, Zagreb, Croatia (I.B.); Lillebaelt Hospital, Kolding, Denmark (E.G.); and the
Wolfson Institute of Preventive Medicine,
Barts and the London School of Medicine
and Dentistry, Queen Mary University of
London, London (J.K.M.). Address reprint requests to Dr. de Jong-van den
Berg at the Department of Pharmacoepidemiology and Pharmacoeconomics,
University of Groningen, A. Deusinglaan
1, 9713 AV Groningen, the Netherlands,
or at [email protected].
*Members of the European Surveillance
of Congenital Anomalies (EUROCAT)
Antiepileptic Study Working Group are
listed in the Appendix.
N Engl J Med 2010;362:2185-93.
Copyright 2010 Massachusetts Medical Society.
Conclusions
The use of valproic acid monotherapy in the first trimester was associated with significantly increased risks of several congenital malformations, as compared with no
use of antiepileptic drugs or with use of other antiepileptic drugs.
n engl j med 362;23 nejm.org june 10, 2010
2185
The
n e w e ng l a n d j o u r na l
Me thods
EUROCAT Database
of
m e dic i n e
We used the EUROCAT antiepileptic-study databases, which included data on affected live births,
stillbirths, fetal deaths after 20 or more weeks of
gestation, and terminations of pregnancy after
prenatal diagnosis for the years 1995 through
2005 from 19 population-based EUROCAT registries in 14 countries (for more information, see
Section 1 of the Supplementary Appendix, available with the full text of this article at NEJM
.org).19 The study sample consisted of 3,881,592
live births and stillbirths, of which 98,075 involved a major congenital malformation.
The standard data recorded for each registration are described in EUROCAT Guide 1.3.20 Mul- Study Design
tiple sources are used to ascertain pregnancy out- We searched PubMed, Web of Science, and Emcomes with malformations (registrations).21 Data base for studies addressing exposure to valproic
2186
Country
Births with
Malformation
number
Samrn et al.14
Germany, Finland,
and the Netherlands
Kaaja et al.24
Finland
Sabers et al.23
Denmark
Vajda et al.
15
Wide et al.16
17
19721990
Malformation
Rate
% (95% CI)
184
16
8.7 (5.413.7)
61
6.6 (2.615.7)
30
6.7 (1.921.3)
Australia
89
15
16.9 (10.526.0)
Sweden
268
26
9.7 (6.713.8)
United States
149
16
10.7 (6.316.8)
Meador et al.12
United Kingdom
and United States
69
12
17.4 (10.228.0)
Morrow et al.13
United Kingdom
Wyszynski et al.
715
44
6.2 (4.68.2)
All studies
19722005
1565
135
8.6 (7.310.1)
19722005
1565
118
7.5 (6.39.0)
* According to the classification of major congenital malformations in the European Surveillance of Congenital Anomalies (EUROCAT) registry, based on the International Classification of Diseases, 10th Edition, 17 malformations were minor and were therefore excluded from the
analysis.
2187
The
n e w e ng l a n d j o u r na l
2188
of
m e dic i n e
R e sult s
A total of 37,154 cases, 39,472 controls without
chromosomal abnormalities (control group 1),
and 11,763 controls with chromosomal abnormalities (control group 2) were included in the
study. The frequency of maternal use of antiepileptic drugs overall in the first trimester of pregnancy was 5.7 per 1000 registrations, and the
frequency of maternal use of valproic acid specifically was 2.0 per 1000. The frequency of exposure to valproic acid was three times as high
among cases (3.3 per 1000 registrations) as among
controls in both groups (1.1 per 1000) (Table 2).
In analyses of cases and the controls in
group 1, exposure to valproic acid monotherapy
during the first trimester as compared with no
exposure to antiepileptic drugs during that period
was associated with significant increases in the
risks of spina bifida, atrial septal defect, cleft palate, hypospadias, polydactyly, and craniosynostosis but not in the risks of microcephaly, tetralogy
of Fallot, pulmonary-valve atresia, diaphragmatic
hernia, ventricular septal defect, hypoplastic right
heart (no exposed cases), gastroschisis, or clubfoot (Table 3). Adjustment for reporting registry,
birth year of the registration, and maternal age
did not substantively affect the results (see Section 3 in the Supplementary Appendix for details).
Using the same control group, we found generally similar associations between valproic acid
exposure and malformations when valproic acid
monotherapy was compared with monotherapy
with another antiepileptic drug with two exceptions. When compared with use of another
antiepileptic drug, valproic acid use was not associated with a significantly increased risk of craniosynostosis but was associated with a significantly
increased risk of ventricular septal defect.
In corresponding analyses comparing cases
with the controls in group 2 (those with chromosomal abnormalities), the results were generally
similar. Separate analyses of the suggested association between valproic acid exposure and limb
reduction showed a significantly increased risk
Table 2. Exposure to Antiepileptic Drugs in the First Trimester of Pregnancy among Cases and Controls with Congenital
Malformations.*
Cases
(N=37,154)
Exposure
no.
No exposure to antiepileptic drugs
Control Group 1
(N=39,472)
no./1000
registrations
no.
Control Group 2
(N=11,763)
no./1000
registrations
no.
no./1000
registrations
36,869
39,290
11,725
285
7.7
182
4.6
38
3.2
223
6.0
155
3.9
32
2.7
122
3.3
45
1.1
13
1.1
Other monotherapy
101
2.7
110
2.8
19
1.6
* Malformations included spina bifida, microcephaly, ventricular septal defect, atrial septal defect, tetralogy of Fallot, pulmonary-valve atresia, hypoplastic right heart, cleft palate, diaphragmatic hernia, gastroschisis, hypospadias, clubfoot,
polydactyly, and craniosynostosis.
Among these patients, 58 received carbamazepine, 21 received lamotrigine, 8 received phenobarbital, 4 received oxcarbazepine, 3 received clonazepam, 2 received phenytoin, 1 received methylphenobarbital, 1 received topiramate, and 3
received unspecified medications.
Among these patients, 65 received carbamazepine, 18 received lamotrigine, 9 received phenobarbital, 7 received oxcarbazepine, 3 received phenytoin, 3 received primidone, 2 received clonazepam, 1 received ethosuximide, 1 received
methylphenobarbital, and 1 received topiramate.
Among these patients, 10 received carbamazepine, 4 received phenobarbital, 2 received lamotrigine, 1 received clonazepam, 1 received oxcarbazepine, and 1 received phenytoin.
Discussion
In a review of published cohort studies, we identified 14 major congenital malformations for which
the risk appeared to be significantly increased in
association with exposure to valproic acid monotherapy during the first trimester of pregnancy as
compared with no exposure to antiepileptic drugs
during the first trimester. We then tested these
indications in a large population-based case
control study and found significant associations
between exposure to valproic acid monotherapy
in the first trimester (as compared with no exposure to antiepileptic drugs) and six of these
2189
The
n e w e ng l a n d j o u r na l
of
m e dic i n e
Table 3. Odds Ratios for Malformations with Exposure to Valproic Acid Monotherapy as Compared with No Antiepileptic-Drug (AED)
Exposure and with Exposure to Monotherapy with Other Antiepileptic Drugs in Control Groups 1 and 2.*
Adjusted Odds Ratio for
Valproic Acid Monotherapy
vs. No AED (95% CI)
Control group 1
12.7 (7.720.7)
5.7 (2.612.3)
Control group 2
16.3 (8.033.4)
3.5 (1.210.0)
Control group 1
2.5 (0.39.7)
1.6 (0.114.7)
Control group 2
2.6 (0.311.6)
1.0 (0.19.8)
Control group 1
1.6 (0.92.7)
2.2 (1.14.4)
Control group 2
1.8 (0.83.9)
1.5 (0.64.2)
2.5 (1.44.4)
3.2 (1.57.0)
3.3 (1.47.4)
2.4 (0.87.0)
Type of Malformation
No. with
Malformation
2,046
27
Nervous system
Spina bifida
Microcephaly
696
Heart
Ventricular septal defect
11,711
8,267
19
19
Control group 1
Control group 2
Tetralogy of Fallot
960
Control group 1
2.8 (0.68.6)
1.5 (0.27.9)
Control group 2
2.8 (0.510.4)
0.9 (0.15.5)
Control group 1
2.8 (0.116.7)
2.4 (0.0193.6)
Control group 2
2.9 (0.119.5)
1.5 (0.0120.7)
Pulmonary-valve atresia
311
85
Control group 1
Control group 1
5.2 (2.89.9)
3.0 (1.27.4)
Control group 2
5.2 (2.212.3)
1.9 (0.65.9)
Control group 2
Cleft palate
2,244
Diaphragmatic hernia
754
13
Control group 1
2.3 (0.39.0)
1.2 (0.18.9)
Control group 2
2.4 (0.310.7)
0.7 (0.16.1)
1.1 (0.06.5)
1.2 (0.024.0)
1.1 (0.07.6)
0.7 (0.015.6)
Control group 1
4.8 (2.98.1)
6.7 (2.915.2)
Control group 2
6.3 (2.615.2)
4.1 (1.115.0)
Gastroschisis
798
Control group 1
Control group 2
Hypospadias (male outcome
only)
2190
5,395
32
Table 3. (Continued.)
Adjusted Odds Ratio for
Valproic Acid Monotherapy
vs. No AED (95% CI)
Control group 1
1.6 (0.73.7)
1.3 (0.53.9)
Control group 2
2.2 (0.86.7)
1.2 (0.34.7)
2.2 (1.04.5)
7.1 (1.828.4)
2.4 (0.96.4)
4.4 (0.822.6)
Control group 1
6.8 (1.818.8)
4.9 (0.755.2)
Control group 2
7.0 (1.722.9)
2.9 (0.435.8)
Type of Malformation
No. with
Malformation
3,676
Limb
Clubfoot
Polydactyly
3,500
Control group 1
Control group 2
Craniosynostosis
520
* Control group 1 included registrations without chromosomal abnormalities, and control group 2 registrations with chromosomal abnormalities. For the number of cases with no exposure to valproic acid, see Section 3 in the Supplementary Appendix, available with the full text of
this article at NEJM.org.
A case or control may have been counted in more than one subgroup.
Odds ratios were adjusted for reporting registry, birth year, and maternal age unless otherwise indicated.
Odds ratios were adjusted for birth year and maternal age only.
Microcephaly and clubfoot occurred without spina bifida.
Odds ratios were not adjusted because of the small number of exposed cases.
recommended avoiding valproic acid in pregnancy, if possible, on the basis of evidence that exposure to valproic acid is associated with an increased risk of major congenital malformations
and poor cognitive outcomes and confers a higher
risk than that associated with exposure to other
antiepileptic drugs.9
For malformations seen less frequently, our
study was able to rule out very large risks but not
smaller risks. The confidence limits were wide,
showing that even a study of nearly 4 million pregnancies is not enough to address a potentially
moderate association between rare malformations
and relatively rare drug exposures.
A limitation of our study, as discussed above,
is the lack of information on potential confound
ers. Furthermore, we used controls with malformations instead of those without malformations, since EUROCAT does not include detailed
population-based data on pregnancy outcomes
without malformations. An advantage of using
controls with malformations is that it minimizes
the potential for recall bias and other possible
sources of differential exposure ascertainment,
although such biases would be unlikely to influence the results, since most drug information
was recorded before the outcome of pregnancy
was known. Use of controls with malformations
2191
The
n e w e ng l a n d j o u r na l
for comparison could lead to a conservative estimation of the risk associated with valproic acid
exposure if some of the malformations present
in the control group were also associated with
this exposure; however, by design we excluded
from the control groups malformations previously associated with valproic acid exposure. The
rate of valproic acid exposure was similar in the
two control groups (1.1 per 1000), and the point
estimates for the control group with chromosomal abnormalities were similar but slightly
higher than those for the control group without
chromosomal abnormalities in comparisons of
exposure to an antiepileptic drug with no such
exposure. We therefore concluded that there was
likely to be little or no contamination of our
control groups with malformation types associated with valproic acid exposure and that underestimation of odds ratios because of this bias was
unlikely.
Although the relative risks of several malformations were increased in association with exposure to valproic acid during the first trimester, it
should be recognized that the absolute rates of
specific malformations are low, and the majority
of children born to mothers who take valproic
acid do not have malformations. For example, the
baseline prevalence of spina bifida is about 0.5
cases per 1000 (see Section 2 in the Supplementary Appendix). We calculated an adjusted odds
ratio of 12.7 for the risk of spina bifida when
comparing exposure to valproic acid with no
exposure to an antiepileptic drug (Table 3); the
absolute risk of having a child with spina bifida
is approximately 0.6% in cases of exposure to valproic acid monotherapy during the first trimester. The estimated absolute risks for the other
five malformations after exposure are as follows:
of
m e dic i n e
atrial septal defect, 0.5%; cleft palate, 0.3%; hypospadias, 0.7%; polydactyly, 0.2%; and craniosynostosis, 0.1%. In determining whether to prescribe antiepileptic drugs, as well as which drug
to prescribe, several factors must be taken into
account, among them the goal of optimizing
seizure control in the individual patient. The
decision should be made by the patient and her
clinician after consideration of the benefits and
risks of various agents.
In summary, we found that exposure to val
proic acid during the first trimester was associated
with increased risks of six specific malformations,
as compared with no exposure to antiepileptic
drugs, and the risks of five of these six malformations remained significantly increased when we
compared valproic acid exposure with exposure to
other antiepileptic drugs. Our findings provide
further support for the recommendation of the
American Academy of Neurology to avoid the use
of valproic acid, if possible, in pregnant women.9
Since switching drugs during or just before pregnancy is difficult, the risks associated with valproic acid use should be routinely considered in
choosing therapy for women with childbearing
potential.
The EUROCAT Central Database is supported in part by the
European Union Public Health Programme, with a variety of
sources of public funding for individual registries. Additional
funding was obtained from GlaxoSmithKline for a study of lamo
trigine, during which the antiepileptic-study database was constructed. GlaxoSmithKline was not involved in the present study.
Drs. Garne and Barisic report that their registry received funding from GlaxoSmithKline for the data submitted to the lamo
trigine study.
Dr. Jentink reports receiving travel reimbursements from
GlaxoSmithKline through the University of Ulster. No other potential conflict of interest relevant to this article was reported.
We thank J. Morrow and K. Wide for providing us with more
detailed information about the cases than was available in their
reports and D. Wellesley for case review.
Appendix
Members of the EUROCAT Antiepileptic Study Working Group include the following: C. Verellen-Dumoulin (Centre de Gntique
Humaine Institut de Pathologie et de Gntique), V. Nelen (Provinciaal Instituut voor Hygiene), Belgium; I. Barisic (Childrens University Hospital Zagreb), Croatia; E. Garne (Lillebaelt Hospital, Kolding), Denmark; B. Khoshnood (Institut National de la Sant et de la
Recherche Medicale), B. Doray (Registre des Malformations Congenitales dAlsace), France; S. Poetzsch (Otto-von-Guericke Universitt
Megdeburg), A. Wiesel (Johannes Gutenberg Universitt, Geburtenregister Mainzer Modell), Germany; M. OMahony (Health Service
Executive), Ireland; A. Pierini (Istituto di Fisiologia Clinica del Consiglio Nazionale delle Ricerche), F. Rivieri (Azienda Ospedaliero
Universitaria di Ferrara), Italy; M. Gatt (Department of Health Information and Research), Malta; M. Bakker (University Medical Center
Groningen, University of Groningen), the Netherlands; K. Melve (Norwegian Institute of Public Health, Medical Birth Registry of Norway), Norway; A. Latos-Bielenska, J.P. Mejnartowicz (Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu), Poland; I. Portillo (Direccion Salud Publica, Departamento Sanidad, Gobierno Vasco), Spain; M.-C. Addor (Registre Vaudois des Malformations),
Switzerland; D. Tucker (Swansea National Health Service Trust, Congenital Anomaly Register and Information Service for Wales), D.
Wellesley (Southampton University Hospitals Trust), United Kingdom.
2192
http://www.eurocat-network.eu/content/
EUROCAT-Guide-1.3.pdf.)
21. Idem. EUROCAT member registries.
(Accessed May 14, 2010, at http://www
.eurocat-network.eu/ABOUTUS/Member
Registries/MembersAndRegistry
Descriptions/AllMembers.)
22. The Anatomical Therapeutic Chemical Classification System with Defined
Daily Doses (ATC/DDD): guidelines for
ATC classification and DDD assignment.
Version 13. Geneva: World Health Organization Collaborating Centre for Drug
Statistics Methodology, 2003.
23. Sabers A, Dam M, A-Rogvi-Hansen B,
et al. Epilepsy and pregnancy: lamotrigine
as main drug used. Acta Neurol Scand
2004;109:9-13.
24. Kaaja E, Kaaja R, Hiilesmaa V. Major
malformations in offspring of women
with epilepsy. Neurology 2003;60:575-9.
25. Rodrguez-Pinilla E, Arroyo I, Fondevilla J, Garca MJ, Martnez-Fras ML.
Prenatal exposure to valproic acid during
pregnancy and limb deficiencies: a casecontrol study. Am J Med Genet 2000;90:
376-81.
26. Arpino C, Brescianini S, Robert E, et al.
Teratogenic effects of antiepileptic drugs:
use of an international database on malformations and drug exposure (MADRE).
Epilepsia 2000;41:1436-43.
27. Perucca E. Birth defects after prenatal
exposure to antiepileptic drugs. Lancet
Neurol 2005;4:781-6.
28. Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health:
the challenge of treating epilepsy in pregnancy. Epilepsia 2004;45:1171-5.
29. Meador KJ, Baker GA, Browning N, et
al. Cognitive function at 3 years of age
after fetal exposure to antiepileptic drugs.
N Engl J Med 2009;360:1597-605.
Copyright 2010 Massachusetts Medical Society.
2193